Frank Rimerman Advisors’s Pfizer PFE Stock Holding History

Frank Rimerman Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.95M	Sell	164,115 -10,769	-6%	-$282K	0.22%	70
2026 Q1	$4.91M	Buy	174,884 +10,872	+7%	+$289K	0.32%	51
2025 Q4	$4.08M	Sell	164,012 -32,958	-17%	-$831K	0.26%	58
2025 Q3	$5.02M	Buy	196,970 +42,634	+28%	+$1.05M	0.32%	47
2025 Q2	$3.74M	Buy	154,336 +13,743	+10%	+$321K	0.25%	61
2025 Q1	$3.56M	Buy	140,593 +118,471	+536%	+$3.1M	0.28%	58
2024 Q4	$587K	Sell	22,122 -75,752	-77%	-$2.05M	0.04%	272
2024 Q3	$2.83M	Sell	97,874 -4,013	-4%	-$117K	0.2%	82
2024 Q2	$2.85M	Buy	101,887 +101,573	+32,348%	+$2.8M	0.2%	86
2024 Q1	$8.71K	Hold	314	–	–	﹤0.01%	178
2023 Q4	$9.04K	Buy	+314	New	+$9.49K	﹤0.01%	173

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Frank Rimerman Advisors's PFE Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its Pfizer (PFE) stake by 6.2% in Q2 2026, selling an estimated $282K and leaving 164,115 shares worth $3.95M. The position accounts for 0.22% of the portfolio, ranked #70.

Frank Rimerman Advisors first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $5.02M in Q3 2025. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Frank Rimerman Advisors held 164,115 shares of Pfizer worth $3.95M as of Q2 2026.
Frank Rimerman Advisors sold 10,769 Pfizer shares in Q2 2026, an estimated $282K.
Pfizer made up 0.22% of Frank Rimerman Advisors's portfolio in Q2 2026, its #70 holding.
Frank Rimerman Advisors first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
Frank Rimerman Advisors's Pfizer position peaked at $5.02M in Q3 2025.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.